Non-small cell lung cancer · line 2 · Sotorasib monotherapy (KRAS G12C+ NSCLC, 2L+)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-SOTORASIB-KRAS |
| ID | IND-NSCLC-2L-KRAS-G12C-SOTORASIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-NSCLC |
| Sources | SRC-CODEBREAK200-JOHNSON-2023 SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Standard-track 2L KRAS G12C+ NSCLC. Adagrasib (separate Indication) preferred for active brain metastases. Replaces existing IND-NSCLC-KRAS-G12C-MET-2L (which is retained but should be deprecated — it points to same regimen).
Used By
Algorithms
ALGO-NSCLC-METASTATIC-2L- ALGO-NSCLC-METASTATIC-2L